200 related articles for article (PubMed ID: 19337591)
1. Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses.
Lopez MV; Viale DL; Cafferata EG; Bravo AI; Carbone C; Gould D; Chernajovsky Y; Podhajcer OL
PLoS One; 2009; 4(4):e5119. PubMed ID: 19337591
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic improvement of a stroma-targeted CRAd by incorporating motives responsive to the melanoma microenvironment.
Viale DL; Cafferata EG; Gould D; Rotondaro C; Chernajovsky Y; Curiel DT; Podhajcer OL; Veronica Lopez M
J Invest Dermatol; 2013 Nov; 133(11):2576-2584. PubMed ID: 23604101
[TBL] [Abstract][Full Text] [Related]
3. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.
Zhu ZB; Chen Y; Makhija SK; Lu B; Wang M; Rivera AA; Yamamoto M; Wang S; Siegal GP; Curiel DT; McDonald JM
Int J Oncol; 2006 Nov; 29(5):1319-29. PubMed ID: 17016667
[TBL] [Abstract][Full Text] [Related]
4. Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth.
Lopez MV; Blanco P; Viale DL; Cafferata EG; Carbone C; Gould D; Chernajovsky Y; Podhajcer OL
Mol Cancer Ther; 2006 Oct; 5(10):2503-11. PubMed ID: 17041094
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells serve as a "Trojan horse" for oncolytic adenovirus delivery in the treatment of mouse prostate cancer.
Li ZL; Liang X; Li HC; Wang ZM; Chong T
Acta Pharmacol Sin; 2016 Aug; 37(8):1121-8. PubMed ID: 27345628
[TBL] [Abstract][Full Text] [Related]
6. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.
Zhu ZB; Makhija SK; Lu B; Wang M; Wang S; Takayama K; Siegal GP; Reynolds PN; Curiel DT
J Thorac Oncol; 2006 Sep; 1(7):701-11. PubMed ID: 17409940
[TBL] [Abstract][Full Text] [Related]
7. A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy.
Hakkarainen T; Hemminki A; Curiel DT; Wahlfors J
Int J Mol Med; 2006 Oct; 18(4):751-9. PubMed ID: 16964432
[TBL] [Abstract][Full Text] [Related]
8. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
[TBL] [Abstract][Full Text] [Related]
9. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.
Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT
Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979
[TBL] [Abstract][Full Text] [Related]
10. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
11. Synthetic Tumor-Specific Promoters for Transcriptional Regulation of Viral Replication.
Lopez MV; Cafferata EG; Viale DL; Podhajcer OL
Methods Mol Biol; 2017; 1651():113-130. PubMed ID: 28801903
[TBL] [Abstract][Full Text] [Related]
12. A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers.
Wang X; Su C; Cao H; Li K; Chen J; Jiang L; Zhang Q; Wu X; Jia X; Liu Y; Wang W; Liu X; Wu M; Qian Q
Mol Cancer Ther; 2008 Jun; 7(6):1598-603. PubMed ID: 18566230
[TBL] [Abstract][Full Text] [Related]
13. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment.
Davydova J; Le LP; Gavrikova T; Wang M; Krasnykh V; Yamamoto M
Cancer Res; 2004 Jun; 64(12):4319-27. PubMed ID: 15205347
[TBL] [Abstract][Full Text] [Related]
14. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency.
van Beusechem VW; van den Doel PB; Grill J; Pinedo HM; Gerritsen WR
Cancer Res; 2002 Nov; 62(21):6165-71. PubMed ID: 12414643
[TBL] [Abstract][Full Text] [Related]
15. Absent in melanoma 2 enhances anti-tumour effects of CAIX promotor controlled conditionally replicative adenovirus in renal cancer.
Chai D; Qiu D; Zhang Z; Yuchen Shi S; Wang G; Fang L; Li H; Li H; Tian H; Zheng J
J Cell Mol Med; 2020 Sep; 24(18):10744-10755. PubMed ID: 32725966
[TBL] [Abstract][Full Text] [Related]
16. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.
Stoff-Khalili MA; Rivera AA; Nedeljkovic-Kurepa A; DeBenedetti A; Li XL; Odaka Y; Podduturi J; Sibley DA; Siegal GP; Stoff A; Young S; Zhu ZB; Curiel DT; Mathis JM
Breast Cancer Res Treat; 2008 Mar; 108(1):43-55. PubMed ID: 17508279
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma.
Harada A; Uchino J; Harada T; Nakagaki N; Hisasue J; Fujita M; Takayama K
Cancer Sci; 2017 Jan; 108(1):116-123. PubMed ID: 27783867
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.
Sonabend AM; Ulasov IV; Tyler MA; Rivera AA; Mathis JM; Lesniak MS
Stem Cells; 2008 Mar; 26(3):831-41. PubMed ID: 18192232
[TBL] [Abstract][Full Text] [Related]
19. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer.
Yamamoto M; Davydova J; Wang M; Siegal GP; Krasnykh V; Vickers SM; Curiel DT
Gastroenterology; 2003 Oct; 125(4):1203-18. PubMed ID: 14517802
[TBL] [Abstract][Full Text] [Related]
20. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells.
He X; Liu J; Yang C; Su C; Zhou C; Zhang Q; Li L; Wu H; Liu X; Wu M; Qian Q
Hum Gene Ther; 2011 Mar; 22(3):283-92. PubMed ID: 20846024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
